ArticleJournal of clinical medicine2025

Evaluation of Dose Reduction Factors and Impact on Progression-Free Survival in Patients Treated with CDK 4/6 Inhibitors.

Ali Kaan Güren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.